Is Rofecoxib effective for the chemoprevention of Colorectal Adenomas?
- Baron, J.A., Sandler, R.S., Bresalier, R.S., Quan, H., Riddell, R., Lanas, A., Bolognese, J.A., Oxenius, B., Horgan, K., Loftus, S., Morton, D.G., 2006. A Randomized Trial of Rofecoxib for the Chemoprevention of Colorectal Adenomas. Gastroenterology 131, 1674–1682.
- 2,587 subjects with a recent history of adenomas
- Investigators randomised subjects to receive daily placebo or 25 mg rofecoxib.
- Colonoscopic follow-up evaluation was planned for 1 and 3 years after randomisation.
- Adenoma recurrence was less frequent for rofecoxib subjects than for those randomised to placebo (41% vs 55%; 24% reduction in risk).
- The chemopreventive effect was more pronounced in the first year (35% reduction in risk) than in the subsequent 2 years (19% reduction in risk).
- Rofecoxib was associated with increased risks of significant upper gastrointestinal events and serious thrombotic cardiovascular events.
- Yes (with confidence)
- Although seen to be effective, Rofecoxib had serious side effects from its level of toxicity.